PAT Implementation Will Depend On FDA-Industry Collaboration, AstraZeneca Exec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry must be willing to discuss unfavorable data with FDA for process analytical technology to work, AstraZeneca CMC Director Robert Timko says. FDA is working to ensure consistency between its review centers and field offices as part of the PAT implementation process.
You may also be interested in...
GMP Oversight To Get FDA-Wide Coordination Under New Cmte.
The Council on Pharmaceutical Quality will oversee implementation of the initiative, which covers aseptic processing, quality systems, computerized systems in clinical trials, process analytical technologies and combination products.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Amgen Aranesp, Vectibix Setbacks Illustrate Risks Of Real World Trials
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products